Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $35.6, with 3.75 million shares of worth about $133.57 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 18.71% during that period and on July 16, 2025 the price saw a loss of about -2.49%. Currently the company’s common shares owned by public are about 425.59M shares, out of which, 332.24M shares are available for trading.
Stock saw a price change of -0.75% in past 5 days and over the past one month there was a price change of 2.18%. Year-to-date (YTD), RPRX shares are showing a performance of 32.98% which increased to 39.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.05 but also hit the highest price of $36.69 during that period. The average intraday trading volume for Royalty Pharma plc shares is 4.79 million. The stock is currently trading -0.37% below its 20-day simple moving average (SMA20), while that difference is up 3.86% for SMA50 and it goes to 16.09% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 425.59M outstanding shares and institutions hold larger chunk of about 77.25% of that.
The stock has a current market capitalization of $20.02B and its 3Y-monthly beta is at 0.54. PE ratio of stock for trailing 12 months is 14.52, while it has posted earnings per share of $2.45 in the same period. Its PEG reads 1.33 and has Quick Ratio of 1.56 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 1.98% while standing at 1.86% over the month.
Stock’s fiscal year EPS is expected to rise by 6.28% while it is estimated to increase by 14.40% in next year. EPS is likely to grow at an annualized rate of 10.91% for next 5-years, compared to annual growth of -21.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on May 16, 2025 offering an Overweight rating for the stock and assigned a target price of $51 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Neutral in their note to investors on June 03, 2024, suggesting a price target of $28 for the stock. On June 14, 2022, UBS Resumed their recommendations, while on May 13, 2022, Scotiabank Initiated their ratings for the stock with a price target of $53. Stock get a Buy rating from Goldman on April 27, 2022.
